Thelansis’s “Locally Advanced or Metastatic HR+/HER2- Breast Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Locally advanced or metastatic HR+/HER2- breast cancer is driven by estrogen receptor signaling and represents the most common mBC subtype. Because biomarker discordance and acquired mutations are common, comprehensive molecular profiling (ESR1, PIK3CA, AKT1, PTEN, gBRCA) is mandatory. The frontline standard remains CDK4/6 inhibitors combined with endocrine therapy. Upon progression, management relies heavily on precision medicine: PIK3CA-mutated tumors are treated with inavolisib or alpelisib, capivasertib targets PIK3CA/AKT1/PTEN-altered disease, and the oral SERD elacestrant addresses ESR1-mutated, endocrine-resistant tumors. Patients with germline BRCA mutations benefit from PARP inhibitors (olaparib, talazoparib). Crucially, traditional salvage chemotherapy is being rapidly displaced by antibody-drug conjugates (ADCs); sacituzumab govitecan and trastuzumab deruxtecan—now approved even for HER2-low and HER2-ultralow expression—serve as preferred later-line standards. Management remains incurable but increasingly prolonged, requiring bone-modifying agents and early palliative integration to optimize quality of life.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Locally Advanced or Metastatic HR+/HER2- Breast Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Locally Advanced or Metastatic HR+/HER2- Breast Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.